来那度胺在弥漫大B细胞淋巴瘤治疗中的研究进展

Research progress of lenalidomide applied in treatment of diffuse large B cell lymphoma

来那度胺作为第二代免疫调节剂,具有免疫调节、抗肿瘤、抗血管生成、调节肿瘤微环境等多重作用,其疗效优于沙利度胺,而神经病变、嗜睡、便秘等不良反应明显减轻,现已被美国食品和药物管理局批准用于治疗多发性骨髓瘤和骨髓增生异常综合征。近年来越来越多的临床研究表明来那度胺对于弥漫大B细胞淋巴瘤也有效,其单药应用或联合化疗对初治及复发难治性弥漫大B细胞亦显示出一定的疗效。

As one of second-generation of immune modulator agents, lenalidomide has a complex mechanism of action that involves immune regulation, direct anti-tumor, anti-angiogenesis, modulation of the tumor microenvironment, and so on. Compared with thalidomide, lenalidomide has better treatment effect and less adverse reactions, such as neuropathy, somnolence, constipation and so on. Lenalidomide has been approved by the United States Food and Drug Administration for the treatment of multiple myeloma and myelodysplastic syndromes. In recent years, an increasing number of clinical studies have shown that lenalidomide applied in the treatment of diffuse large B-cell lymphoma is also effective. Either lenalidomideor monotherapy or combined with chemotherapy for previously untreated and relapsed/refractory diffuse large B-cell can achieve a certain effect.